Top Markets
#1 Seeker Seeker +49.88%
#2 Helium Helium +43.34%
#3 TENDIES TENDIES +31.18%
#4 Pons Pons +26.01%
#5 pipedog pipedog +21.90%
#6 Zylo Ecosystem Zylo Ecosystem +21.65%
#7 Bounce Bounce +19.30%
#8 UnifAI Network UnifAI Network +18.93%
#9 ZKsync ZKsync +14.63%
#10 Zora Zora +14.06%
Coin of the day
Seeker Seeker
Ayarlar
Dil
TüRKçE
Para birimi
USD
Tema
Poseida Therapeutics, Inc. Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc.

PSTX
Hisse Senetlerindeki Sıralama #10560
Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical... Poseida Therapeutics, Inc., a San Diego-based clinical-stage biopharmaceutical firm established in 2014, is dedicated to advancing novel therapeutic solutions for conditions with significant unmet medical needs. Its pipeline prominently features several advanced cell therapies. For instance, P-PSMA-101, an autologous CAR-T cell therapy, is currently undergoing Phase I clinical trials for individuals battling metastatic castrate-resistant prostate cancer (mCRPC). Additionally, Poseida is progressing two other CAR-T candidates through Phase I: P-BCMA-ALLO1 targets relapsed/refractory multiple myeloma, while P-MUC1C-ALLO1 is designed to address a variety of solid tumors, such as breast, ovarian, and other epithelial-derived malignancies. The company is further exploring allogeneic (off-the-shelf) CAR-T approaches with candidates like P-CD19CD20-ALLO1, aimed at B cell malignancies and certain autoimmune conditions, and P-BCMACD19-ALLO1, which is in preclinical development for multiple myeloma. Another allogeneic CAR-T, P-PSMA-ALLO1, is also being developed for mCRPC. Beyond cell therapies, Poseida's portfolio includes clinical-stage liver-directed gene therapies, specifically P-OTC-101 and P-FVIII-101, alongside other exploratory allogeneic dual CAR candidates. Collaborative efforts include a research and licensing agreement with Takeda Pharmaceutical Company Limited.
Hisse Fiyatı
$9.50
Son senkronizasyon: 2025-01-08
Piyasa Değeri
$819.52M
Değişim (1 gün)
0.00%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret Poseida Therapeutics, Inc. (PSTX)

Kategori

Healthcare
Poseida Therapeutics, Inc. (PSTX) için gelir
Sep 2024 itibarıyla gelir TTM: $150.86M
Poseida Therapeutics, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) $150.86M'dir. 2022 yılında şirketin geliri $130.36M önceki yıla göre artış 2021 yılındaki $31.24K gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Poseida Therapeutics, Inc. için 2016 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
2026 (TTM) $150.86M 133.15%
2023 $64.70M -50.37%
2022 $130.36M 417,217.08%
2021 $31.24K 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 -100.00%
2017 $2.99M -69.44%
2016 $9.77M 0.00%
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B 8,268.33%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B 3,891.36%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B 10,336.52%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B 1,376.89%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH